Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®? (devimistat) for Patients with Metastatic Pancreatic Cancer
Stock Information for Rafael Holdings Inc. Class B
Loading
Please wait while we load your information from QuoteMedia.